J&J Remicade Ulcerative Colitis Indication Possible By September
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
J&J/Centocor'sRemicade is on track to become the first biologic with an ulcerative colitis claim following FDA's priority review designation for a March sBLA submission